jRCT1030190046进行中（未招募）不适用
The ADVANCE in Japan, A longitudinal Study of age-related comorbidities in people with hemophilia (The ADVANCE in Japan)
No sponsor0 个研究点目标入组 600 人开始时间: 2019年2月23日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 600
- 主要终点
- incidence rates of cardiovascular events
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 40age old over 至 No limit（—）
- 性别
- All
入选标准
- •Mild, moderate or severe congenital Hemophilia A or B
- •Age 40 years or over
- •If informed consent is required by the regulations of each facility, consent must be obtained.
排除标准
- •Acquired hemophilia
- •Other coagulation disorder
- •Patients with Factor VIII and Factor IX activity >40% at the time of diagnosis
- •Under 40 years old
- •If informed consent is required by the regulations of each facility, it is not possible to obtain it.
- •If informed consent is not required, if the patient requests that the information cannot be provided
结局指标
主要结局
incidence rates of cardiovascular events
The principal objectives of the ADVANCE Study will be to determine the incidence rates of cardiovascular events.
次要结局
- emergence of inhibitors(over time)
- anti-coagulation usage and death rates
- death from CVD incidences and rates
- CVD incidence vs expected rates
- causes of death
- comorbidities rates comparison
- treatment for other comorbidities
- management and outcomes
研究者
相似试验
已完成
不适用
JAPANESE PROSPECTIVE REAL WORLD REGISTRY OF NIVOLUMAB PLUS IPILIMUMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED, ADVANCED OR METASTATIC RENAL CELL CARCINOMA (ARCC) CATEGORIZED INTO IMDC INTERMEDIATE/POOR RISKS (J-ENCORE)ADVANCED OR METASTATIC RENAL CELL CARCINOMAJPRN-UMIN000036772Bristol-Myers Squibb K.K. Ono Pharmaceutical CO.,LTD.286
招募中
不适用
RANGER AV Japan studyAVF for hemodialysisjRCT2032240406Boston Scientific Japan K.K.186
进行中（未招募）
不适用
TRISCEND JAPAN Trial (TRISCEND JAPAN)Severe or greater TRjRCT2022220045Edwards Lifesciences Japan LLC45
已完成
不适用
SIMPLIFY JAPAN (SIMPLIFY JAPAN)Type 2 DiabetesjRCT1041210151SANOFI68
招募中
不适用
The ADVANCE in JapaHaemophiliaJPRN-jRCT1030190046agao Azusa600